PD-1/PD-L1 inhibitors were associated with modest survival and response benefits in recurrent or metastatic nasopharyngeal carcinoma, though findings were based largely on heterogeneous and single-arm studies.
Source: Medicine
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
